501(c)3 transforming how LongCovid, ME/CFS, Lyme+ and Alzheimer’s are studied, diagnosed, and treated. Leading the #LongCovid Research Consortium.
United States
Joined October 2020
- Tweets3K
- Following2K
- Followers14.4K
- Likes3.6K
PolyBio retweeted
Our study on virus-specific T cell activation in Long COVID (LC) is up on bioRxiv! We identify a subset of people with LC with persistently elevated activation of CD8 T cells targeting spike and/or EBV lytic antigens, consistent with viral persistence.
biorxiv.org/content/10.64898…
PolyBio retweeted
Invivyd and the SPEAR Study Group Announce Initiation of “FLINTLOCK” Phase 2 Study of VYD2311, a Monoclonal Antibody for the Potential Treatment of Long COVID or Post-Vaccination Syndrome investors.invivyd.com/news-r…
PolyBio retweeted
It's madness that most people in the healthspan-extension space do little to control the activity of #viral, bacterial, #parasite and other pathogens that can hack their bodies over time.
Come listen to me talk at the Liberty Hotel next Thurs where I will discuss how to change this by optimizing anti-pathogen treatment approaches!
eventbrite.com/e/health-inno…
PolyBio retweeted
UCSF researchers studying 1800+ people with long COVID found the illness may hide deep in body tissues rather than show up in blood tests.
Their goal is to pinpoint the virus’s lasting effects and develop targeted cures for different patients.
menshealth.com/health/a71130…
PolyBio retweeted
We received feedback that folks are not so eager to enter a placebo-controlled trial for fear of being in the placebo arm. So, for our trial looking at low-dose rapamycin for #LongCOVID we now have an open-label extension added to the trial so everyone gets to try it! Reach out!
PolyBio retweeted
The time is now!
Save the date! PolyBio’s Spring symposium will take place on Friday, May 22 11-5 PM ET. It will feature project updates on Long COVID, ME/CFS, Alzheimer’s & chronic tick-borne disease research that is advancing how we diagnose & treat IACIs. Sign up now:
us02web.zoom.us/webinar/regi…
PolyBio retweeted
Excited to announce the decentralization of our lumbrokinase trial @polybioRF, now open it to patients with #LongCOVID, #MECFS, and #chronicLyme throughout the cont. US. You will receive the drug by mail & complete VIRTUAL study visits. Enroll at [email protected]!
PolyBio retweeted
People with #IACCI #LongCOVID #chronicLyme #MECFS symptoms -- please consider filling out this quick (~10 min) form about your experiences accessing medical care! Your answers will be used to improve our clinical practice & medical education at CoRE.
redcap.mountsinai.org/redcap…
PolyBio retweeted
What is persistent #SARS-CoV-2 Spike doing in gut tissue in situ?
In our new preprint, we used spatial transcriptomics, RNAscope, GeoMx DSP, and multiplex IF to investigate biopsies from #LongCOVID
The immune dysfunction happen on spike + regions of LC.
biorxiv.org/content/10.64898…
PolyBio retweeted
In this collaborative study funded by @polybioRF, we have detected gene signatures specific of Long covid tissue regions. Persistent SARS-CoV-2 antigen is not biologically inert in tissue, in fact super active with both immune suppression and activation.
@PutrinoLab @AmyProal
PolyBio retweeted
So glad to join today’s HHS #Lyme & Invisible Illness panel! Via @polybioRF we are validating novel diagnostic tests to identify chronic infections missed by current bloodwork. These diagnostics will help make the invisible visible in Chronic Lyme, Long COVID & related conditions
PolyBio retweeted
We (@PutrinoLab @polybioRF) are still recruiting for a #NYC-area 6-month clinical trial on the potential of sirolimus (#rapamycin) to treat #LongCOVID symptoms in adults! If you're local & could be eligible, please sign up here: coresinai.org/trials/sirolim…
PolyBio retweeted
We are looking to close this trial out this year and give the #LongCOVID community some answers. If you are in New York City please consider reaching out!
A reminder that our clinical trial with @polybioRF @VirusesImmunity @PutrinoLab is still recruiting adults with #LongCOVID in New York City! We are trialing a 6-month course of #HIV antivirals #Truvada and #Maraviroc. Sign up here: coresinai.org/trials/antivir…
PolyBio retweeted
So grateful to be included in this phenomenal #LongCOVID phenotyping work led by the amazing Max Qian. Pulling together data from multiple @polybioRF research sites, Max went deep into phenotyping patients based on symptom presentation. There are so many insights in this beast 1/
PolyBio retweeted
We're proud to be bookending the @polybioRF symposium:
- Our Scientific Director @microbeminded2 will be opening with an overview of PolyBio research from 11-11:10am ET
- Our Nash Family Director @PutrinoLab will be presenting on combination antivirals from 5-5:10pm ET
PolyBio retweeted
Reminder that @PutrinoLab @ CoRE is still enrolling #LongCOVID patients in multiple clinical trials supported by @polybioRF! All patients must be >18 and located in/able to travel to New York City.
PolyBio retweeted
V. excited to join the SPEAR (Spike Protein Elimination and Recovery) team with @MichaelPelusoMD @microbeminded2 @PutrinoLab @Invivyd to study whether broadly neutralizing mAb can treat Long COVID and post-vaccination syndrome subset driven by persistent spike protein.
investors.invivyd.com/news-r…
PolyBio retweeted
So glad to join this SPEAR Study Group! LongCOVID & Post Vaccine Syndrome patients have waited way too long for expanded research on how #monoclonal antibodies - including those with broadly neutralizing activity - may improve their symptoms. We intend to change that!
BREAKING: Anecdotes are wonderful - let’s go get the data! Invivyd & leading researchers launch SPEAR Study Group to explore effects of mAb therapy on people suffering from Long COVID & post-vaccination syndrome. investors.adagiotx.com/news-… @UCSF @polybioRF @michaelpelusoMD @microbeminded2 @putrinolab #LongCOVID #LongCovid
PolyBio retweeted
We are so excited about our clinical trial of low dose rapamycin for people with #LongCOVID. Understanding the mechanisms behind WHO this helps and WHY is crucial for establishing safe and effective treatments for people with LC and ultimately other complex chronic illnesses. 🙏
Join a clinical trial assessing the safety and efficacy of sirolimus in adults with Long COVID. For more information, contact [email protected].
ALT Recruitment flyer from the Icahn School of Medicine at Mount Sinai titled “Participants Needed for Long COVID Clinical Trial.” The flyer describes a study investigating the effects of a 12-week protocol of low-dose Sirolimus (rapamycin) versus placebo in adults with Long COVID. To be eligible, participants need a confirmed diagnosis of Long COVID and a positive COVID test, must be 18 or older, and live in the NYC area. The flyer explains that, if selected, participants will attend five in-person visits over six months, with blood draws, saliva collection, and online surveys. Study drug or placebo will be taken for 12 weeks in increasing doses. Compensation up to $150 is offered. Contact email: [email protected]. Study effective dates are 2/11/2025 to 1/13/2026. Principal Investigator: Dr. David Putrino, PT, PhD. The flyer also includes cartoon-style illustrations of a person thinking, a checklist, and a person speaking with a healthcare provider.
PolyBio retweeted
This one drug at 4mg every week has gave me back much of my life. Understanding exactly what it is and isn't doing will help millions.
A new clinical trial for Long COVID at @CoRESinai! If you are in the NYC area and interested in our Sirolimus clinical trial, please email [email protected] 🙏🏼